An Old Antidepressant Just Extended Mouse Lifespan by 17%. Here's Why Calcium May Be the Hidden Clock of Aging

Key Takeaways

• Mianserin extended median mouse lifespan by 17% in one study
• Human oral equivalent dose ≈ 227 mg/day exceeds approved 30‑90 mg range
• Agranulocytosis risk requires CBC monitoring every 4 weeks
• Calcium‑mediated S100A6 reduction identified as likely anti‑aging mechanism
• Drug cost negligible but safety profile currently unfavorable for self‑use

Pulse Analysis

The longevity signal from mianserin stems from its ability to blunt calcium‑induced S100A6 buildup, a pathway that accelerates cellular senescence. In the mouse model, intermittent intraperitoneal dosing lowered intracellular IP3‑mediated calcium release, dampening downstream inflammatory cascades and extending life by nearly a fifth. While the finding aligns with broader research linking calcium dysregulation to aging, it remains a single‑study observation in one sex of short‑lived rodents, so extrapolation to humans demands caution.

Translating the mouse regimen to humans reveals a stark dosage mismatch. FDA body‑surface‑area calculations suggest a systemic exposure equivalent to 56.8 mg daily, but accounting for the drug’s 22 % oral bioavailability pushes the required oral dose to roughly 227 mg per day—almost three times the maximum approved antidepressant dose. This supratherapeutic level amplifies known risks, especially agranulocytosis, which appears in about 1 in 2,000‑4,000 treated patients and mandates CBC monitoring every four weeks. Additional side effects such as sedation, weight gain, and orthostatic hypotension further erode the risk‑benefit balance for long‑term use.

From a market perspective, acquiring pharmaceutical‑grade mianserin is inexpensive (UK prescription ≈ $12.5 for a 28‑tablet pack, translating to $15‑30 per month at therapeutic doses). However, the safety concerns and lack of human pharmacokinetic data outweigh the low cost. Compared with other longevity candidates like rapamycin or metformin, mianserin offers a distinct calcium‑centric mechanism but lacks robust clinical validation. Until repeat‑dose toxicology, human PK, and efficacy trials emerge, the compound remains a speculative anti‑aging tool rather than a viable therapeutic option.